A Phase I, Randomised, Single-Blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4831 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2017
At a glance
- Drugs AZD 4831 (Primary)
- Indications Heart failure
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 10 Jun 2017 Biomarkers information updated
- 05 Jan 2017 Status changed from suspended to discontinued.
- 09 Nov 2016 Status changed from recruiting to suspended.